Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 2/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 6/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 6/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.37 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30389164 | 1.00 | USP30 (0.42) | USP30ESR2BACE1LIPEPDCD1 | |
| SCHEMBL30389125 | 0.94 | PDCD1 (0.42) | USP30ESR2BACE1LIPEPDCD1 | |
| SCHEMBL25314286 | 0.94 | PDCD1 (0.42) | USP30ESR2BACE1LIPEPDCD1 | |
| SCHEMBL23202653 | 0.87 | RAF1 (0.40) | USP30ESR2BACE1LIPEMAP3K5 | |
| SCHEMBL25314447 | 0.85 | MAP3K5 (0.47) | USP30ESR2LIPENR1H2MAP3K5 | |
| SCHEMBL30389317 | 0.85 | MAP3K5 (0.47) | USP30ESR2LIPENR1H2MAP3K5 | |
| SCHEMBL20293441 | 0.84 | PDCD1 (0.49) | PDCD1CD274 | |
| SCHEMBL31354371 | 0.84 | GRAMD1A (0.45) | USP30PDCD1CD274 | |
| SCHEMBL29593538 | 0.84 | PDCD1 (0.49) | PDCD1CD274 | |
| SCHEMBL23198768 | 0.83 | PARP1 (0.40) | USP30BACE1LIPEPDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234970-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| EP-4174066-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-05-03 | — | — | EP | disclosed |
| EP-4174066-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234970-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CD274, PDCD1, PDCD1LG2 | USP30 4392/4885ESR2 4315/4885BACE1 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.